NYSE:HRC - Hill-Rom Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hill-Rom Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $108.61 -0.31 (-0.28 %) (As of 02/19/2020 04:00 PM ET) Add Compare Today's Range$108.54Now: $108.61▼$110.1050-Day Range$106.49MA: $111.39▼$116.3752-Week Range$93.88Now: $108.61▼$117.10Volume330,974 shsAverage Volume442,321 shsMarket Capitalization$7.28 billionP/E Ratio48.92Dividend Yield0.77%Beta0.88 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:HRC Previous SymbolNYSE:HB CUSIP43147510 CIK47518 Webhttp://www.hill-rom.com/ Phone312-819-7200Debt Debt-to-Equity Ratio1.09 Current Ratio1.52 Quick Ratio1.17Price-To-Earnings Trailing P/E Ratio48.92 Forward P/E Ratio19.57 P/E Growth1.78 Sales & Book Value Annual Sales$2.91 billion Price / Sales2.50 Cash Flow$8.10 per share Price / Cash Flow13.41 Book Value$24.17 per share Price / Book4.49Profitability EPS (Most Recent Fiscal Year)$5.08 Net Income$152.20 million Net Margins5.15% Return on Equity21.87% Return on Assets7.63%Miscellaneous Employees10,000 Outstanding Shares66,991,000Market Cap$7.28 billion Next Earnings Date4/24/2020 (Estimated) OptionableOptionable Receive HRC News and Ratings via Email Sign-up to receive the latest news and ratings for HRC and its competitors with MarketBeat's FREE daily newsletter. HRC Rates by TradingView Hill-Rom (NYSE:HRC) Frequently Asked Questions What is Hill-Rom's stock symbol? Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC." How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom? Hill-Rom declared a quarterly dividend on Friday, November 8th. Stockholders of record on Monday, December 16th will be paid a dividend of $0.21 per share on Tuesday, December 31st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, December 13th. View Hill-Rom's Dividend History. How were Hill-Rom's earnings last quarter? Hill-Rom Holdings, Inc. (NYSE:HRC) posted its quarterly earnings data on Friday, January, 24th. The medical technology company reported $1.13 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The medical technology company had revenue of $685 million for the quarter, compared to the consensus estimate of $684.01 million. Hill-Rom had a net margin of 5.15% and a return on equity of 21.87%. The firm's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.02 EPS. View Hill-Rom's Earnings History. When is Hill-Rom's next earnings date? Hill-Rom is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for Hill-Rom. What guidance has Hill-Rom issued on next quarter's earnings? Hill-Rom updated its FY20 earnings guidance on Friday, January, 24th. The company provided earnings per share (EPS) guidance of $5.50-5.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.52. The company issued revenue guidance of +1-2% to $2.94-2.97 billion, compared to the consensus revenue estimate of $2.94 billion. What price target have analysts set for HRC? 3 analysts have issued 1 year price targets for Hill-Rom's stock. Their forecasts range from $116.00 to $138.00. On average, they anticipate Hill-Rom's share price to reach $127.50 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for Hill-Rom. What is the consensus analysts' recommendation for Hill-Rom? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom. What are Wall Street analysts saying about Hill-Rom stock? Here are some recent quotes from research analysts about Hill-Rom stock: 1. According to Zacks Investment Research, "Hill-Rom exited the second quarter of fiscal 2019 on a strong note with better-than-expected numbers. The company saw a solid year-over-year increase in domestic revenues, driven by sturdy performance in Patient Support Systems and Front Line Care. We are upbeat to note the company’s strong momentum across its diversified product portfolio which includes Centrella Smart+ bed, Welch AllynConnex Spot Monitor, Monarch Airway Clearance System, Integrated Table Motion for the da Vinci Xi Surgical System. The acquisition of Voalte buoys optimism as it boosts Hill-Rom’s digital and mobile communications platform. Overall, Hill-Rom has outperformed its industry in the past six months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenue growth was sluggish in the quarter." (6/6/2019) 2. Needham & Company LLC analysts commented, "HRC announced that it has entered into a definitive agreement to acquire Voalte (private) for $180M up front and up to $15M in commercial-based milestones. HRC believes it can absorb the dilutive impact of the deal in FY19, expects the transaction to close in F3Q19, and estimates the deal to become increasingly accretive beginning in FY20. Voalte offers smartphone and web-based applications that enable caregivers to communicate securely and provides managers data analytics tools, respectively. The Voalte deal seems to make financial (accretive to revenue growth and margins) and strategic (further diversifies HRC away from capital equipment sales and allows for cross-selling opportunities in its care communications business) sense, in our view, and we reiterate our Buy rating." (3/11/2019) Has Hill-Rom been receiving favorable news coverage? Headlines about HRC stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hill-Rom earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Hill-Rom. Are investors shorting Hill-Rom? Hill-Rom saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 1,620,000 shares, a decline of 12.4% from the December 31st total of 1,850,000 shares. Based on an average trading volume of 392,500 shares, the short-interest ratio is presently 4.1 days. Approximately 2.4% of the company's stock are short sold. View Hill-Rom's Current Options Chain. Who are some of Hill-Rom's key competitors? Some companies that are related to Hill-Rom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR). What other stocks do shareholders of Hill-Rom own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Paypal (PYPL), AK Steel (AKS), Endologix (ELGX), Walt Disney (DIS), Chipotle Mexican Grill (CMG), Micron Technology (MU), Mastercard (MA), AT&T (T) and Twilio (TWLO). Who are Hill-Rom's key executives? Hill-Rom's management team includes the folowing people: Mr. John P. Groetelaars, Pres, CEO & Director (Age 52)Mr. Carlos Alonso-Marum, Sr. VP & Pres of International (Age 60)Mr. Paul Johnson, Sr. VP & Pres of Patient Support Systems (Age 54)Mr. Steven J. Strobel, Sr. Advisor (Age 61)Ms. Barbara W. Bodem, Sr. VP & CFO (Age 51) Who are Hill-Rom's major shareholders? Hill-Rom's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (2.76%), State Street Corp (2.48%), Bank of New York Mellon Corp (1.63%), Bank of Montreal Can (1.58%), Bank of America Corp DE (1.24%) and Charles Schwab Investment Management Inc. (1.22%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom. Which major investors are selling Hill-Rom stock? HRC stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Jennison Associates LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, Credit Suisse AG, Lord Abbett & CO. LLC, AQR Capital Management LLC and State Street Corp. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom. Which major investors are buying Hill-Rom stock? HRC stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc., AXA, State of New Jersey Common Pension Fund D, Acadian Asset Management LLC and UBS Group AG. View Insider Buying and Selling for Hill-Rom. How do I buy shares of Hill-Rom? Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Hill-Rom's stock price today? One share of HRC stock can currently be purchased for approximately $108.61. How big of a company is Hill-Rom? Hill-Rom has a market capitalization of $7.28 billion and generates $2.91 billion in revenue each year. The medical technology company earns $152.20 million in net income (profit) each year or $5.08 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom. What is Hill-Rom's official website? The official website for Hill-Rom is http://www.hill-rom.com/. How can I contact Hill-Rom? Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected] MarketBeat Community Rating for Hill-Rom (NYSE HRC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 361 (Vote Outperform)Underperform Votes: 377 (Vote Underperform)Total Votes: 738MarketBeat's community ratings are surveys of what our community members think about Hill-Rom and other stocks. Vote "Outperform" if you believe HRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2020 by MarketBeat.com StaffFeatured Article: How is the discount rate different from the Federal Funds rate?
